The enlarged group was re-admitted to AIM and Euronext Growth on 20th January 2020 and completed a placing of £5.3 million on 31 January 2020.

Open Orphan Plc are building a leading European specialist pharmaceutical services company which includes a focus on orphan drug services by acquiring and consolidating a series of European services companies.

hVIVO Plc is an industry leading services provider in the viral challenge studies and virology laboratory services. It has developed a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases.

It is hoped the merger will result in synergies across the Enlarged Group with each business providing complementary services with limited overlap in existing capabilities and customers.

Jeffreys Henry LLP acted as the Reporting Accountant in respect of the merger and subsequent re-admission.